Показать сообщение отдельно
  #2  
Старый 02.08.2013, 11:21
DrTatyana DrTatyana вне форума ВРАЧ
Почетный участник форума
      
 
Регистрация: 07.07.2008
Адрес: Россия
Сообщений: 13,750
Сказал(а) спасибо: 3
Поблагодарили 5,252 раз(а) за 5,106 сообщений
DrTatyana этот участник имеет превосходную репутацию на форумеDrTatyana этот участник имеет превосходную репутацию на форумеDrTatyana этот участник имеет превосходную репутацию на форумеDrTatyana этот участник имеет превосходную репутацию на форумеDrTatyana этот участник имеет превосходную репутацию на форумеDrTatyana этот участник имеет превосходную репутацию на форумеDrTatyana этот участник имеет превосходную репутацию на форумеDrTatyana этот участник имеет превосходную репутацию на форумеDrTatyana этот участник имеет превосходную репутацию на форумеDrTatyana этот участник имеет превосходную репутацию на форумеDrTatyana этот участник имеет превосходную репутацию на форуме
Новости

2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors.AUMassad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, Solomon D, Wentzensen N, Lawson HW, 2012 ASCCP Consensus Guidelines Conference J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S1-S27.

Цитата:
Management of abnormal cervical cytology in women aged 21 to 24 years

Revised guidelines for the evaluation and treatment of abnormal cervical cytology and histology have been issued by the American Society for Colposcopy and Cervical Pathology (ASCCP) in collaboration with multiple professional societies and the Centers for Disease Control and Prevention [18]. A major change from previous recommendations is the differentiation of management of abnormal cytology in women ages 21 to 24 years from those age 25 or older, based upon the higher prevalence of human papillomavirus infection and low risk of cervical cancer in younger women. Thus, for younger women, HPV testing is not used in the evaluation of most abnormalities and colposcopy is advised only if abnormal cytology results are severe or recurrent.
HPV triage for women ages 30 and older with LSIL on cervical cytology

Цитата:
Recommendations regarding management of low-grade squamous intraepithelial lesion (LSIL) on cervical cytology have been revised, in accord with updated guidelines for the evaluation and treatment of abnormal cervical cytology and histology issued by the American Society for Colposcopy and Cervical Pathology (ASCCP) [18]. For women ages 30 and older with LSIL, results of human papillomavirus (HPV) testing should be used to triage further evaluation. Women with LSIL and a negative HPV test should be followed with repeat cytology and HPV co-testing at 12 months. Women with LSIL and a positive HPV test should be evaluated with colposcopy. Women with LSIL who were initially screened with cytology alone and do not have an HPV test result should also be evaluated with colposcopy. In general, the ASCCP guidelines incorporate co-testing rather than cytology alone into the follow-up of many abnormalities for women in this age group.

For women ages 25 to 29 years, cytology alone without HPV testing is recommended for cervical cancer screening. Recommendations for management of LSIL in this age group have not changed. Women ages 25 to 29 years with LSIL, even those who inadvertently had HPV testing, should be managed based upon cytology alone and should be evaluated with colposcopy.